Pfizer to invest up to US$500 million in public drug developers

Pfizer to invest up to US$500 million in public drug developers

Pfizer Inc said on Tuesday it will invest up to US$500 million into publicly traded drug developers to fund their treatment candidates and provide access to the U.S. drugmaker's scientific expertise.

FILE PHOTO: The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S.
FILE PHOTO: The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016. REUTERS/Andrew Kelly/File Photo

REUTERS: Pfizer Inc said on Tuesday it will invest up to US$500 million into publicly traded drug developers to fund their treatment candidates and provide access to the U.S. drugmaker's scientific expertise.

Pfizer said it will make non-controlling investments in the biotechs with small- to medium-sized market capitalizations, but did not identify them.

The move comes at a time when the COVID-19 pandemic has led drugmakers to delay their clinical trials testing various therapies.

Pfizer said its Breakthrough Growth Initiative program, under which it was making the investment, allows partner companies to access its research, clinical development and manufacturing resources.

(Reporting by Dania Nadeem in Bengaluru; Editing by Shinjini Ganguli)

Source: Reuters

Bookmark